CompletedNot Applicable

A Study of Nivolumab Plus Ipilimumab in Participants With Renal Cell Cancer in the Real World Setting in Japan

Japan286 participantsStarted 2019-09-19

Plain-language summary

The purpose of the observational study is to evaluate the safety and effectiveness of combination therapy with nivolumab and ipilimumab in Japanese participants with advanced or metastatic renal cell carcinoma (aRCC) in the real-world setting in Japan.

Who can participate

Age range20 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Histological confirmation of Renal Cell Carcinoma (RCC) * No prior systemic therapy for RCC * Participants who are planned to start treatment with nivolumab and ipilimumab regimen in the timeframe between after IRB approval to enrollment-end date * International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk category Intermediate/Poor Exclusion Criteria: * Participants who are enrolled in a post marketing safety study on nivolumab plus ipilimumab combination therapy in Japan * Pregnant and/or lactating women * Participants who are judged to be inappropriate by investigator Other protocol-defined inclusion/exclusion criteria apply.

What they're measuring

Objective Response Rate (ORR)

Timeframe: Up to 5 years

Trial details

NCT IDNCT04043975

SponsorBristol-Myers Squibb

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2024-08-23

View on ClinicalTrials.gov More Advanced or Metastatic Renal Cell Carcinoma trials